Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
20 July, 2018 06:55 IST
Cipla receives final approval for generic Pulmicort Respules
Source: IRIS | 17 Nov, 2017, 10.16AM
Comments  |  Post Comment

Cipla, a global pharmaceutical company, today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Budesonide Inhalation Suspension, 0.25mg/2mL, 0.5mg/2mL, and 1mg/2mL from the United States Food and Drug Administration (USFDA) to market a generic version of Astrazeneca's Pulmicort Respules.

Cipla's Budesonide Inhalation Suspension, 0.25mg/2mL, 0.5mg/2mL, and 1mg/2mL, are AN-rated generic equivalents of Astrazeneca's Pulmicort Respules® and are indicated for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age. The product is available for shipping immediately.

Pulmicort Respules® and generic equivalents had U.S. sales of approximately USD 825M for the 12-month period ending September 2017, as reported by IMS Health.

Shares of the company gained Rs 11.6, or 1.95%, to trade at Rs 605.20. The total volume of shares traded was 22,486 at the BSE (9.43 a.m., Friday).



Cipla Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Yes Bank partners with 10 smart cities to tackle development challenges - 19-Jul-2018 17:36
Govt to infuse capital worth Rs 17.9 bn in Allahabad Bank - 19-Jul-2018 16:17
Trigyn Technologies wins contract from U.S. Army Picatinny Arsenal - 19-Jul-2018 16:11
Kotak Mahindra Bank quarterly net climbs 12.3% to Rs 10.25 bn - 19-Jul-2018 15:58
Bajaj Finance quarterly profit surges 83% - 19-Jul-2018 15:32
Tata Motors bags order to supply electric vehicles to Cognizant - 19-Jul-2018 13:19
Infosys Foundation signs accord with Bangalore Metro - 19-Jul-2018 11:49
Lupin receives tentative USFDA approval for generic Tadalafil tablets - 19-Jul-2018 11:34
Zydus Cadila gets USFDA's final nod for Piroxicam capsules - 19-Jul-2018 10:26
MCX takes preventive measures against technical glitches - 19-Jul-2018 10:19
Tata Power launches electric vehicle charging stations in Hyderabad - 18-Jul-2018 15:45
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer